Why Europe's Sickest Patients Stay Home Now

Europe's remote monitoring market races toward $11.22B by 2030, with the UK's NHS turning hospital care into a home affair

10 Jul 2026

Something is changing in how Europe treats its sick. Hospitals are emptying out, not because patients need less care, but because they're getting it somewhere else: their own living rooms.

The UK is driving this shift faster than anywhere else on the continent. NHS Long Term Plan initiatives have pushed community-based care into the mainstream, and the numbers back up the ambition. Europe's remote patient monitoring market stood at $6.87 billion in 2025. By 2030, analysts expect it to hit $11.22 billion, growing at a steady annual clip near 10%.

Virtual wards explain much of that surge. Hospital-at-home programs once felt experimental. Now they're standard practice, woven into national care strategies rather than bolted on as pilot projects. Three companies dominate the space: Philips, Medtronic, and GE Healthcare. Each has built connected devices and analytics platforms that plug directly into provider IT systems, letting health networks scale virtual care without reinventing their infrastructure. Markets and Markets singled out all three as the players shaping how governments deliver digital health at national scale.

For companies in health tech, diagnostics, or enterprise software, the opportunity extends well past hospital walls. Continuous data streams from these monitoring platforms create demand for cybersecurity, interoperability standards, and new reimbursement models. That ripple effect touches nearly every corner of the healthcare supply chain. Providers already report shorter readmission cycles and better capacity management, which makes the business case harder to dismiss with each passing quarter.

Patients feel the difference most directly, though. Instead of shuttling back to clinics for routine checks, they wear sensors, use connected diagnostic tools, and receive AI-driven alerts that catch problems before they escalate. It's clinical-grade monitoring, minus the waiting room.

As national payers refine reimbursement policy across Europe, that access is set to spread. Early adopters proved the model works. Mid-tier markets are next in line, and the growth curve through 2030 suggests they won't be waiting long to catch up.